Rett syndrome (RTT) is an early-onset neurological disorder primarily affecting females, leading to severe cognitive and physical disabilities. Recent studies indicate that an imbalance of redox homeostasis and exacerbated inflammatory responses are key players in the clinical manifestations of the disease. Emerging evidence highlights that the p75 neurotrophin receptor (p75NTR) is implicated in the regulation of oxidative stress (OS) and inflammation. Thus, this study is aimed at investigating the effects of p75NTR modulation by LM11A-31 on fibroblasts derived from RTT donors. RTT cells were treated with 0.1 µM of LM11A-31 for 24 h, and results were obtained using qPCR, immunofluorescence, ELISA, and Western blot techniques. Our findings demonstrate that LM11A-31 reduces OS markers in RTT fibroblasts. Specifically, p75NTR modulation by LM11A-31 restores protein glutathionylation and reduces the expression of the pro-oxidant enzyme NOX4. Additionally, LM11A-31 significantly decreases the expression of the pro-inflammatory mediators interleukin-6 and interleukin-8. Additionally, LM11A-31 normalizes the expression levels of transcription factors involved in the regulation of the antioxidant response and inflammation. Collectively, these data suggest that p75NTR modulation may represent an effective therapeutic target to improve redox balance and reduce inflammation in RTT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11592079PMC
http://dx.doi.org/10.3390/biomedicines12112624DOI Listing

Publication Analysis

Top Keywords

p75ntr modulation
16
oxidative stress
8
expression pro-inflammatory
8
pro-inflammatory mediators
8
rett syndrome
8
modulation lm11a-31
8
additionally lm11a-31
8
lm11a-31
6
p75ntr
5
rtt
5

Similar Publications

Rett syndrome (RTT) is an early-onset neurological disorder primarily affecting females, leading to severe cognitive and physical disabilities. Recent studies indicate that an imbalance of redox homeostasis and exacerbated inflammatory responses are key players in the clinical manifestations of the disease. Emerging evidence highlights that the p75 neurotrophin receptor (p75NTR) is implicated in the regulation of oxidative stress (OS) and inflammation.

View Article and Find Full Text PDF

Small molecule modulation of p75 engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease.

Neurotherapeutics

November 2024

Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA; Wu Tsai Neurosciences Institute, Stanford University, Stanford, CA, USA.

Huntington's disease (HD) is a neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene encoding a mutant huntingtin (mHtt) protein. mHtt aggregates within neurons causing degeneration primarily in the striatum. There is currently a need for disease-modifying treatments for HD.

View Article and Find Full Text PDF

p75NTR mediated chronic restraint stress-induced depression-like behaviors in mice via hippocampal mTOR pathway.

Life Sci

December 2024

State Key Laboratory of Trauma and Chemical Poisoning, Daping Hospital, Army Medical University, Chongqing 400042, China. Electronic address:

Aims: Major depressive disorder (MDD) is an enduring and severe mood disorder. Previous studies have indicated that p75NTR is involved in neuronal survival and death. However, the specific mechanism of p75NTR in depression remains unknown.

View Article and Find Full Text PDF
Article Synopsis
  • A study introduced a recombinant fusion protein called p75ECD-Fc, which combines the extracellular domain of p75 and the Fc fragment of human IgG1, to promote neuronal growth and restore brain function in rats with neonatal hypoxic-ischemic encephalopathy (NHIE).
  • In vitro tests showed that p75ECD-Fc significantly improves cell viability and neurite outgrowth under oxygen-glucose deprivation conditions.
  • In vivo results revealed that p75ECD-Fc reduced brain damage and neurological issues more effectively than hypothermia, while also enhancing neuronal survival and shifting glial cell phenotypes, suggesting its potential as a therapeutic option for NHIE.
View Article and Find Full Text PDF

Antiretroviral drugs have made significant progress in treating HIV-1 and improving the quality of HIV-1-infected individuals. However, due to their limited permeability into the brain HIV-1 replication persists in brain reservoirs such as perivascular macrophages and microglia, which cause HIV-1-associated neurocognitive disorders. Therefore, it is highly desirable to find a novel therapy that can cross the blood-brain barrier (BBB) and target HIV-1 pathogenesis in brain reservoirs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!